Lead antibody MB0109 targets C1q and uniquely inhibits both classical complement cascade and C1q-mediated macrophage/microglial activation — two key drivers of neuroinflammationMB0109 demonstrated ...

The intellectual property will enhance Liberate Bio’s LNP platform for selective programming of monocytes and macrophages.

This episode, titled Rethinking KDIGO Guidance and Payer Models in the Era of Targeted IgA Nephropathy Therapies, features expert nephrologists discussing the following critical questions: What ...

Patients with type 2 diabetes who received sodium-glucose cotransporter-2 inhibitors demonstrated a nearly 50% lower risk for systemic autoimmune rheumatic disease vs. those who received dipeptidyl ...

Liberate Bio, Inc., a biotechnology company developing genetic medicines that deliver RNA therapies directly to immune cells, announces that it has secured exclusive and non-exclusive licenses to key ...

Between four and 10 million people in the U.S. have fibromyalgia. Many doctors look askance at the disorder, leading some ...

A look at the biologics, gene therapies, and vaccines most likely to reshape care —and manufacturing—in the year ahead.

Zealand Pharma’s shares fell 32% in early morning trading Friday after its Roche-partnered asset petrelintide failed to meet investor expectations in a mid-stage clinical trial.

A new analysis using data from the Department of Veterans Affairs’ Million Veteran Program (MVP) found individuals living with type 2 diabetes had a substantially lower risk of major adverse ...

Hello Dose introduces the DROP (TM) Method, a structured four-step framework designed to support clinician-supervised GLP-1 medication management with behavioral and educational guidance.

Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. | After 27 years with Bavarian Nordic, including 12 as CEO, Paul ...